ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Just simmering

<< Previous

Bullboard Posts

Next >>

Post by bball67on Oct 10, 2022 5:22pm

971 Views

Post# 35016126

Just simmering

In a good situation. There is a steady bid at $6 with a strong hand. Not alot of sellers. Low volume. We may simmer awhile longer. News will come. Low boil coming soon. December and January the stock should breakout, boiling over with the possibilities and discovered by new holders. Exciting times coming soon. Can't wait!! My pot is full, can't buy anymore shares.

<< Previous

Bullboard Posts

Next >>

Two Venture-listed mining stocks file NI 43-101 reports